In a four-week study of 1,587 men, researchers report that men who suffer from premature ejaculation (PE) had an average intravaginal ejaculatory latency time (IELT) of 1.8 minutes, compared to 7.3 minutes in men who did not. Men with PE and their fema
Body fatness was associated with more cardiovascular disease risk factors even among healthy, aerobically fit men, according to a report today in an obesity-themed issue of Circulation: Journal o
A new Australian prostate cancer clinical trial hopes to provide clear evidence to men with prostate cancer about the best time to start hormone treatment in terms of prolonging life, balanced against the effects on their quality of life.The ra
Rates of heart attack and coronary death among British middle aged men have fallen steadily since the late 1970s, but this has been largely offset by an increase in the rate of diagnosed angina, finds a study in this week's
Despite fears of shame and stigma, most HIV-positive men choose to confide their health status to their mothers, according to a new University of Florida study. When deciding whether to tell, the men
Men with higher levels of physical activity may reduce their risk of dying from prostate cancer and slow the progression of the disease, according to a study in the May 9 issue of Archives of Intern
Men who include more dairy products in their diets, especially low-fat varieties, may have a lower risk of developing type 2 diabetes, according to a study in the May 9 issue of Archives of Internal
Researchers in Sweden have found that a compound taken from male sweat stimulates the brains of gay men and straight women but not heterosexual men, which raises the possibility that homosexual brains are different.The findings supports other e
Men with prostate cancer generally make treatment decisions based on differences in the information they receive rather than their own preferences, according to a new review. Published in the May 1, 2006 issue of
Researchers writing in the January 15, 2005 issue of CANCER, a peer-reviewed journal of the American Cancer Society, say few patients get tested for osteoporosis during treatment. Moreover, even men with other risk factors for osteoporosis, such as smoking or receiving the hormone treatment for a long time, are still unlikely to receive prevention or treatment.
Osteoporosis is a disease characterized by brittle, easily fractured bones that is associated with significant morbidity, mortality, and healthcare cost. It is caused by dysregulation of the hormone-regulated bone remodeling system that leads to a loss of bone mineral density. Risk factors for male osteoporosis include age-associated hormone changes, alcoholism, smoking, some medications, including those used in the treatment of prostate cancer.
Osteoporosis can be prevented and even treated using a wide range of therapies. Common prevention measures include calcium and vitamin D supplements, regular exercise. Screening test such as the dual-energy X-ray absorptiometry (DXA) scan is also available. But, even now, there is no established national consensus guiding doctors of when and what to prescribe. Treatment strategies include bisphosphonates, which have been shown to prevent further bone loss, but it is inconvenient, sometimes expensive, and may cause serious side effects. To find out how clinicians were managing osteoporosis risk in the U.S. in year 2003 and identify factors that might predict who gets treated, Tawee Tanvetyanon, M.D. from Loyola University Chicago Stritch School of Medicine reviewed the sampled records of 184 prostate cancer patients who received androgen deprivation therapy (ADT), which is known to raise the risk of osteoporosis.
Dr. Tanvetyanon found that "the majority of patients undergoing ADT did not receive osteoporosis prevention or treatment," even when they reported other risk factors, as well. Only about one in seven (14.7 percent) eligible patients received any sort of osteoporosis management. Fewer than one in ten (8.7 percent) received at least one DXA scan within three years, and only one in twenty (4.9 percent) was prescribed a bisphosphonate. The only factor that predicted clinical management of osteoporosis risk and disease was the presence of bony metastases (prostate cancers that had spread to the bones). Analysis also showed that primary care physicians were the most aggressive at managing osteoporosis while cancer specialists were the least.
http://www.interscience.wiley.com/cancer-newsroom